Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02978404
Recruitment Status : Recruiting
First Posted : December 1, 2016
Last Update Posted : February 27, 2019
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Centre hospitalier de l'Université de Montréal (CHUM)

Brief Summary:

Stereotactic radiosurgery (SRS) is increasingly administered as the sole treatment of brain metastases, in order to spare acute and long term side effects associated with whole brain radiotherapy. Local control of SRS treated lesions is good, but patients tend to develop additional brain metastases subsequently.

Nivolumab is a modulator of the immune system. Treatment with Nivolumab is associated with an increase in local control and survival in patients with non-small cell lung cancer and clear cell renal cell carcinoma. In the presence of Nivolumab, treatment of brain metastases with SRS may trigger an immune reaction against cancer. Therefore, the combination of SRS with Nivolumab may reduce the development of new brain metastases and improve patient survival.

The purpose of this study is to assess the effect of combining Nivolumab and SRS in controlling cancer progression. SRS will be administered to patients while they are receiving Nivolumab.


Condition or disease Intervention/treatment Phase
Clear-Cell Metastatic Renal Cell Carcinoma Non Small Cell Lung Cancer Metastatic Brain Metastases, Adult Drug: Nivolumab Radiation: Radiosurgery Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Multi-centre Study, of Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases From Non-small Cell Lung Cancer and Renal Cell Cancer
Actual Study Start Date : June 2, 2017
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: Radiosurgery and Nivolumab

Interventions: Nivolumab (240mg IV q2week or 480mg IV q4week) and Radiosurgery (15-20 Gray (Gy) in 1 fraction)

Upon entering this trial, patients with metastatic brain disease(s) will receive Nivolumab. One to 2 week after receiving the first dose of Nivolumab, radiosurgery will be delivered at doses ranging from 15 to 20 Gy in 1 fraction to the brain metastases to a maximum volume of 10 cubic centimeter.

Drug: Nivolumab
Nivolumab is administered to patients to a maximum of 2 year.

Radiation: Radiosurgery
Up to 10 cubic centimeter of brain metastases will be treated with radiosurgery. The dose of radiosurgery depends on the size of individual metastases.
Other Name: SRS




Primary Outcome Measures :
  1. Intracranial progression-free survival [ Time Frame: 1 year ]

    To evaluate whether the combination SRS with Nivolumab will improve the intracranial progression-free survival of patients.

    Response will be assessed as per RECIST version 1.1.



Secondary Outcome Measures :
  1. Treated brain lesions control rate [ Time Frame: 1 year ]
    Treated brain lesions control will be assessed as per RECIST version 1.1.

  2. Overall survival after receiving Nivolumab. [ Time Frame: 2 years ]

    Overall Survival is assessed at the end of the study at 2 years. A subject will be classified as either alive or dead due to any cause.

    The time to event will be calculated as the time from Day 1 until date of death.

    Day 1 is the date of 1st treatment consisting of an infusion of Nivolumab.


  3. Maximum response rate of distant non-irradiated disease [ Time Frame: 1 year ]
    Response will be assessed as per RECIST version 1.1.

  4. Progression-free survival [ Time Frame: 1 year ]
    Response will be assessed as per RECIST version 1.1.

  5. Correlation between tumor PD-L1 expression and clinical outcomes [ Time Frame: 1 year ]
    Tumor PD-L1 expression level will be correlated with patient overall response rate, loco-regional recurrence free survival and overall survival.

  6. Patient quality of life [ Time Frame: 1 year ]
    Quality of life will be assessed using the the Functional Assessment of Cancer Therapy - General (FACT-G) and the Brain Subscale (FACT-BR) questionnaires. A composite score will be obtained from the score of each subscale. Quality of life decline is the time to the first minimal important difference in the composite score from baseline.

  7. Neurocognitive function, as measured by the HVLT-R [ Time Frame: 1 Year ]
    Neurocognitive function will be assessed using the Hopkins Verbal Learning Test - Revised (HVLT-R). Neurocognitive failure is the time to the first failure on the assessments using the Reliable Change Index. Baseline neurocognitive function will be compared to the test results at 1 year using either a t-test or Wilcoxon-Mann-Whitney test, depending on the normality of the data.

  8. Neurocognitive function, as measured by TMT [ Time Frame: 1 year ]
    Neurocognitive function will be assessed using the Trail Making Test (TMT). Neurocognitive failure is the time to the first failure on the assessments using the Reliable Change Index. Baseline neurocognitive function will be compared to the test results at 1 year using either a t-test or Wilcoxon-Mann-Whitney test, depending on the normality of the data.

  9. Neurocognitive function, as measured by COWA [ Time Frame: 1 Year ]
    Neurocognitive function will be assessed using the Controlled Oral Word Association (COWA). Neurocognitive failure is the time to the first failure on the assessments using the Reliable Change Index. Baseline neurocognitive function will be compared to the test results at 1 year using either a t-test or Wilcoxon-Mann-Whitney test, depending on the normality of the data.

  10. Acute and late toxicity of SRS + Nivolumab [ Time Frame: 1 year ]

    Adverse events will be coded according to MedDRA. The results will be tabulated to examine their frequency, organ systems affected, severity, and relationship to study treatment.

    Terminology Criteria for Adverse Events (CTCAE) V4.03 will be used for grading of AEs. Investigators will provide their assessment of causality as 1) unrelated, 2) unlikely, 3) possibly related, 4) probably, or 5) definitely related.


  11. Imaging indicators of response [ Time Frame: 1 year ]
    Patient response to the treatment will be analysed using the Immune-related Response Evaluation Criteria In Solid Tumors (irRECIST) criteria.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men and women, ≥ 18 years of age
  2. Willing and able to give written informed consent
  3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 within 28 days prior to registration
  4. Radiation Therapy Oncology Group (RTOG) neurological function score of 0-1 within 28 days prior to registration
  5. Histologic diagnosis of NSCLC OR ccRCC
  6. Stage IV cancer with brain metastases (Patients may have untreated primary disease)
  7. Presenting with previously un-irradiated brain metastasis (10 cc maximum volume of brain disease based on the diagnostic screening MRI done within 28 days of registration))
  8. Measurable/evaluable brain disease
  9. Having received less than 4 lines of prior systemic treatments
  10. Ability to be treated with either gamma knife or a linear accelerator based radiosurgery system
  11. Ability to complete neurocognitive exams without assistance
  12. Ability to complete QOL questionnaires with or without assistance
  13. Screening laboratory values must meet the following criteria and should be obtained within 28 days prior to registration:

    • White Blood Cell (WBC) ≥ 2000/uL
    • Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
    • Platelets≥ 100 x 109/L
    • Hemoglobin ≥ 90 g/L (may be transfused)
    • Serum creatinine ≤ 1.5 x Upper Limit of Normal (ULN) or Creatinine Clearance ≥ 50 ml/min (calculated -cockcroft-Gault)
    • Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤3 x ULN without liver metastasis,≤ 5 x ULN with liver metastases
    • Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
  14. Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (28 days plus the time required for Nivolumab to undergo five half-lives) after the last dose of investigational drug
  15. Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of Nivolumab
  16. Women must not be breastfeeding
  17. Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving Nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of Nivolumab product. Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception).

Exclusion Criteria:

  1. Brain metastasis in the brainstem
  2. Patients who experienced prior seizures are eligible, however patients should not have had a seizure within 7 days of registration without the use of corticosteroids.
  3. All other cancer histology other than NSCLC or ccRCC
  4. Patients who cannot undergo MRI
  5. Active, known or suspected autoimmune disease. Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger
  6. Patients with a condition requiring systemic treatment with either corticosteroids including steroids used for treating peritumoral edema (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
  7. Drugs with a predisposition to hepatoxicity should be used with caution in patients treated with Nivolumab-containing regimen
  8. Any underlying medical or psychiatric condition, which in the opinion of the investigator will make the administration of Nivolumab hazardous or obscure the interpretation of AEs, such as a condition associated with frequent diarrhea.
  9. History of prior treatment with a CTLA-4, PD-1 or PD-L1 inhibitor, CD137 agonist, or anti-PD-L2.
  10. Concomitant therapy with any of the following: IL-2, interferon, or other non-study immunotherapy regimens; immunosuppressive agents; other investigation therapies
  11. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (eg, infectious) illness.
  12. Known history of hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
  13. History of allergy to study drug components.
  14. Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02978404


Contacts
Layout table for location contacts
Contact: Philip Wong, MD, FRCPC 15148908254 philip.wong.chum@ssss.gouv.qc.ca
Contact: Diane Trudel, RN 15148908254 diane.dt.trudel.chum@ssss.gouv.qc.ca

Locations
Layout table for location information
Canada, Quebec
Centre Hospitalier de l'Université de Montréal Recruiting
Montreal, Quebec, Canada, H2L 4M1
Contact: Philip Wong, MD, FRCPC    15148908254    philip.wong.chum@ssss.gouv.qc.ca   
Contact: Laura Masucci, MD, FRCPC    15148908254    g.laura.masucci.chum@ssss.gouv.qc.ca   
McGill University Health Centre Recruiting
Montreal, Quebec, Canada, H4A 3J1
Contact: Valerie Panet-Raymond, MD    (514) 934-1934    valerie.panet-raymond@mcgill.ca   
Contact: Marianna Perna    514-934-1934 ext 43191    marianna.perna@muhc.mcgill.ca   
Jewish General Hospital Not yet recruiting
Montréal, Quebec, Canada, H3T 1E2
Contact: Thierry Muanza, MD    514-340-8288    thierry.muanza@mcgill.ca   
Contact: Naeem Iqbal    514-340-8288    naeem.iqbal.ccomtl@ssss.gouv.qc.ca   
Centre Hospitalier Universitaire de Sherbrooke Recruiting
Sherbrooke, Quebec, Canada, J1H 5N4
Contact: Marc-Emile Plourde, MD    819-346-1110 ext 14311    marc-emile.plourde@usherbrooke.ca   
Contact: Sophie Couture    819-346-1110 ext 14311    socouture.chus@ssss.gouv.qc.ca   
Sponsors and Collaborators
Centre hospitalier de l'Université de Montréal (CHUM)
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Principal Investigator: Philip Wong, MD, FRCPC Centre hospitalier de l'Université de Montréal (CHUM)

Layout table for additonal information
Responsible Party: Centre hospitalier de l'Université de Montréal (CHUM)
ClinicalTrials.gov Identifier: NCT02978404     History of Changes
Other Study ID Numbers: 16.206
OZM-080 ( Other Identifier: CRO )
First Posted: December 1, 2016    Key Record Dates
Last Update Posted: February 27, 2019
Last Verified: July 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Centre hospitalier de l'Université de Montréal (CHUM):
radiosurgery
PD-1
Nivolumab

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
Carcinoma, Renal Cell
Brain Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Neoplastic Processes
Pathologic Processes
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Kidney Diseases
Urologic Diseases
Central Nervous System Neoplasms
Nervous System Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Nivolumab